CHINA MEDICAL UNIVERSITY
🇹🇼Taiwan
A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Recruiting
- Conditions
- FruquintinibIrinotecanCapecitabineGastrointestinal Tumours
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 50
- Registration Number
- NCT06169202
- Locations
- 🇨🇳
First Hospital of China Medical University, Shenyang, Liaoning, China
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT06118658
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance
Phase 2
Not yet recruiting
- Conditions
- Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 40
- Registration Number
- NCT06118645
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: Intravenous infusion anti-HER2-CAR-T cell
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 9
- Registration Number
- NCT06101082
- Locations
- 🇨🇳
Phase I Clinical Trials Center Of The First Hospital of China Medical University, Shenyang, Liaoning, China
Effects of Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
Phase 3
Recruiting
- Conditions
- ImmunonutritionPostoperative Adjuvant ChemotherapyGastrointestinal Tumors
- Interventions
- Drug: Immunonutrition （Su yusu)
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 324
- Registration Number
- NCT06085365
- Locations
- 🇨🇳
The First Hospital of China Medical University, Shenyang, Liaoning, China
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Carcinoma
- Interventions
- Biological: Intravenous infusion anti-CEA-CAR-T cell
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 9
- Registration Number
- NCT06013111
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical Univeristy, Shenyang, Liaoning, China
Effects of Different Oxygen Concentrations on Pulmonary Complications in Patients Undergoing Radical Resection of Esophageal Cancer
Phase 4
Recruiting
- Conditions
- Atelectasis, Postoperative
- Interventions
- Drug: 60%OxygenDrug: 30%Oxygen
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 100
- Registration Number
- NCT06013098
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
Not yet recruiting
- Conditions
- TAS 102RegorafenibFruquintinibGastrointestinal Tumours
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 45
- Registration Number
- NCT05993702
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Unresectable or Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFOX/FOLFIRI
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 30
- Registration Number
- NCT05797883
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Effects of Different Inhalation Oxygen Concentrations on Postoperative Atelectasis
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 96
- Registration Number
- NCT05627024
- Locations
- 🇨🇳
the First Hospital of China Medical University, Shenyang, Liaoning, China
© Copyright 2025. All Rights Reserved by MedPath